|
|
Chairman Rick Scott Calls for Transparency of Foreign-Made Generic Drugs, Announces CLEAR LABELS Act to Require Country-of-Origin Labeling |
|
| Chairman Rick Scott led a hearing entitled “Truth in Labeling: Americans Deserve to Know Where Their Drugs Come From,” in which he exposed the serious risks of America’s overreliance on foreign-manufactured, generic drugs and announced his CLEAR LABELS Act, legislation requiring country-of-origin labeling for prescription drugs in the United States. A significant portion of prescription medications are manufactured in Communist China and India, often under limited regulatory oversight, leaving patients and health care providers with little clarity about where their medicines originate. Committee members and expert witnesses evaluated the risks this poses to patient safety and supply-chain resilience and offered potential legislative solutions to curb this crisis and protect America’s drug supply chain. Chairman Scott has been a leading voice in strengthening oversight of America’s pharmaceutical supply chains and confronting the United States’ dangerous overreliance on foreign-manufactured generic drugs. Today’s hearing followed a bipartisan investigative report he led to expose these vulnerabilities and advance greater accountability on these generic drugs. Building on this report, Chairman Scott and Ranking Member Gillibrand have sent more than a dozen letters to federal agencies and industry leaders seeking information and pressing for greater transparency into the generic drugs Americans rely on every day. The committee’s recent hearings on September 17, October 8, and November 19 further examined the risks posed by foreign dependence and explored policy solutions to expand domestic manufacturing and ensure Americans’ access to safe, high-quality medicines. Chairman Scott’s witnesses for today’s hearing included Dr. John Gray, Ph.D., dean’s distinguished professor of operations at Fisher College of Business at The Ohio State University; Dr. Michael Ganio, Pharm.D., senior director, pharmacy practice and quality, at ASHP; and Dr. Stephen W. Schondelmeyer, Pharm.D., Ph.D., professor of pharmaceutical management and economics, College of Pharmacy at the University of Minnesota. Their testimonies highlighted critical vulnerabilities in the U.S. drug supply chain, outlined the risks created by limited visibility into foreign manufacturing practices, and emphasized the need for stronger reporting and country-of-origin labeling requirements to protect patients, support health care providers, and incentivize domestic pharmaceutical manufacturing. Watch Chairman Scott's full remarks HERE or below.  Read more HERE. Lea más AQUÍ. — The U.S. Senate Special Committee on Aging is committed to helping seniors and victims of fraud. If you or someone you know has been a victim of fraud, suspect you or someone you know have been targeted by a scammer, or have questions about common scams, please call the Fraud Hotline at 1-855-303-9470 (open weekdays from 9 a.m. to 5 p.m. Eastern Time) or fill out the web form HERE. If you are looking for materials to help you avoid frauds and scams, the most recent copy of the Committee’s Fraud Book is HERE. — To be the first to find out about the U.S. Senate Special Committee on Aging's actions and statements, follow on X. |
